Iterative Health has successfully raised $77 million to enhance its AI-powered clinical research platform, aiming to broaden its therapeutic focus into cardiology and obesity.
The Massachusetts-based healthtech company plans to utilize this funding to improve trial recruitment and expand its existing capabilities in gastroenterology and hepatology. With a network that includes over 100 research sites across four continents and partnerships with more than 40 stakeholders—ranging from biotech companies to contract research organizations—Iterative Health is positioned to streamline access to clinical trials through its AI-driven platform.
This innovative approach centralizes site access and employs artificial intelligence to effectively match patients with suitable trials, which is expected to significantly enhance site activation and enrollment rates. The funding round was led by Google Ventures and Intrepid Growth Partners, both of which are anticipated to take an active role in the company's growth strategy moving forward.
Furthermore, Iterative’s expansion into cardiology and obesity aligns with increasing regulatory demands for diversity in clinical trials. Agencies like the FDA and EMA are advocating for more inclusive participant representation, echoing the World Health Organization's calls to engage often-overlooked populations. This strategic move not only addresses regulatory pressures but also positions Iterative Health to meet the evolving needs of the healthcare landscape.